Tubastatin A, an HDAC6 inhibitor, alleviates stroke-induced brain infarction and functional deficits: Potential roles of α-tubulin acetylation and FGF-21 up-regulation

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Wang, Zhifei ^a,b   Leng, Yan ^b   Wang, Junyu ^b   Liao, Hsiao Mei ^b   Bergman, Joel ^c   Leeds, Peter ^b   Kozikowski, Alan ^c   Chuang, De Maw ^b  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 21; GLUTAMIC ACID; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; INDOLE DERIVATIVE; NEUROPROTECTIVE AGENT; TUBASTATIN A; TUBULIN;

ACETYLATION; ANIMAL; BRAIN INFARCTION; CELL DEATH; CONVALESCENCE; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MITOCHONDRION; NERVE CELL; NEURITE; PATHOPHYSIOLOGY; RAT; SIGNAL TRANSDUCTION; UPREGULATION;

ACETYLATION; ANIMALS; BRAIN INFARCTION; CELL DEATH; DISEASE MODELS, ANIMAL; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION; GLUTAMIC ACID; HISTONE DEACETYLASE INHIBITORS; HYDROXAMIC ACIDS; INDOLES; MITOCHONDRIA; NEURITES; NEURONS; NEUROPROTECTIVE AGENTS; RATS; RECOVERY OF FUNCTION; SIGNAL TRANSDUCTION; TUBULIN; UP-REGULATION;

EID: 84955119033     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep19626     Document Type: Article

References (36)

1. Chuang, D. M., Leng, Y., Marinova, Z., Kim, H. J. & Chiu, C. T. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci 32, 591-601 (2009).
2. Wang, Z. F., Fessler, E. B. & Chuang, D. M. Beneficial effects of mood stabilizers lithium, valproate and lamotrigine in experimental stroke models. Acta Pharmacol Sin 32, 1433-1445 (2011).
3. Chiu, C. T., Wang, Z., Hunsberger, J. G. & Chuang, D. M. Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacol Rev 65, 105-142 (2013).
4. Hubbert, C. et al. HDAC6 is a microtubule-associated deacetylase. Nature 417, 455-458 (2002).
5. Valenzuela-Fernandez, A., Cabrero, J. R., Serrador, J. M. & Sanchez-Madrid, F. HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions. Trends Cell Biol 18, 291-297 (2008).
6. Rivieccio, M. A. et al. HDAC6 is a target for protection and regeneration following injury in the nervous system. Proc Natl Acad Sci USA 106, 19599-19604 (2009).
7. Ding, H., Dolan, P. J. & Johnson, G. V. Histone deacetylase 6 interacts with the microtubule-associated protein tau. J Neurochem 106, 2119-2130 (2008).
8. Dompierre, J. P. et al. Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation. J Neurosci 27, 3571-3583 (2007).
9. Aoki, M. et al. Early immunohistochemical changes of microtubule based motor proteins in gerbil hippocampus after transient ischemia. Brain Res 669, 189-196 (1995).
10. Luo, T. et al. Upregulation of the GEF-H1 pathway after transient cerebral ischemia. Exp Neurol 263, 306-313 (2015).
11. Chen, Y. T. et al. Expression patterns of histone deacetylases in experimental stroke and potential targets for neuroprotection. Clin Exp Pharmacol Physiol 39, 751-758 (2012).
12. Butler, K. V. et al. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J Am Chem Soc 132, 10842-10846 (2010).
13. Jochems, J. et al. Antidepressant-like properties of novel HDAC6-selective inhibitors with improved brain bioavailability. Neuropsychopharmacology 39, 389-400 (2014).
14. Zhang, L. et al. Tubastatin A/ACY-1215 Improves Cognition in Alzheimer's Disease Transgenic Mice. J Alzheimers Dis 41, 1193-1205 (2014).
15. d'Ydewalle, C. et al. HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease. Nat Med 17, 968-974 (2011).
16. Xu, X., Kozikowski, A. P. & Pozzo-Miller, L. A selective histone deacetylase-6 inhibitor improves BDNF trafficking in hippocampal neurons from Mecp2 knockout mice: implications for Rett syndrome. Front Cell Neurosci 8, 68 (2014).
17. Leng, Y. et al. FGF-21, a novel metabolic regulator, has a robust neuroprotective role and is markedly elevated in neurons by mood stabilizers. Mol Psychiatry 20, 215-223 (2015).
18. Fessler, E. B., Chibane, F. L., Wang, Z. & Chuang, D. M. Potential roles of HDAC inhibitors in mitigating ischemia-induced brain damage and facilitating endogenous regeneration and recovery. Curr Pharm Des 19, 5105-5120 (2013).
19. Bulinski, J. C. Microtubule modification: acetylation speeds anterograde traffic flow. Curr Biol 17, R18-20 (2007).
20. Reed, N. A. et al. Microtubule acetylation promotes kinesin-1 binding and transport. Curr Biol 16, 2166-2172 (2006).
21. Liu, X. A., Rizzo, V. & Puthanveettil, S. V. Pathologies of Axonal Transport in Neurodegenerative Diseases. Transl Neurosci 3, 355-372 (2012).
22. Wakita, H. et al. Axonal damage and demyelination in the white matter after chronic cerebral hypoperfusion in the rat. Brain Res 924, 63-70 (2002).
23. Valeriani, V., Dewar, D. & McCulloch, J. Quantitative assessment of ischemic pathology in axons, oligodendrocytes, and neurons: attenuation of damage after transient ischemia. J Cereb Blood Flow Metab 20, 765-771 (2000).
24. Hollenbeck, P. J. & Saxton, W. M. The axonal transport of mitochondria. J Cell Sci 118, 5411-5419 (2005).
25. Iijima, T. Mitochondrial membrane potential and ischemic neuronal death. Neurosci Res 55, 234-243 (2006).
26. Inagaki, T. et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab 5, 415-425 (2007).
27. Itoh, N. FGF21 as a Hepatokine, Adipokine, and Myokine in Metabolism and Diseases. Front Endocrinol (Lausanne) 5, 107 (2014).
28. Liu, W. Y. et al. The role of fibroblast growth factor 21 in the pathogenesis of liver disease: a novel predictor and therapeutic target. Expert Opin Ther Targets, 1-9 (2014).
29. Suzuki, M. et al. betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol Endocrinol 22, 1006-1014 (2008).
30. Muise, E. S. et al. Downstream signaling pathways in mouse adipose tissues following acute in vivo administration of fibroblast growth factor 21. PLoS One 8, e73011 (2013).
31. Zhang, C. et al. Fibroblast growth factor 21 protects the heart from apoptosis in a diabetic mouse model via extracellular signal-regulated kinase 1/2-dependent signalling pathway. Diabetologia 58, 1937-1948 (2015).
32. Ueno, H., Huang, X., Tanaka, Y. & Hirokawa, N. KIF16B/Rab14 molecular motor complex is critical for early embryonic development by transporting FGF receptor. Dev Cell 20, 60-71 (2011).
33. Gao, L., Cueto, M. A., Asselbergs, F. & Atadja, P. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J Biol Chem 277, 25748-25755 (2002).
34. Wang, Z. et al. Chronic valproate treatment enhances postischemic angiogenesis and promotes functional recovery in a rat model of ischemic stroke. Stroke 43, 2430-2436 (2012).
35. Tsai, L. K. et al. Mesenchymal stem cells primed with valproate and lithium robustly migrate to infarcted regions and facilitate recovery in a stroke model. Stroke 42, 2932-2939 (2011).
36. Wang, Z. F., Wang, J., Zhang, H. Y. & Tang, X. C. Huperzine A exhibits anti-inflammatory and neuroprotective effects in a rat model of transient focal cerebral ischemia. J Neurochem 106, 1594-1603 (2008).